ClinicalTrials.gg
Not yet recruitingNCT07891520SPINUpdated Oct 23, 2026

Efficacy of Seated Physical Activity INtervention(SPIN) for Wheelchair Users With Multiple Sclerosis

An interventional study of SPIN exercise-training and Control Condition (WELL) in Multiple Sclerosis, sponsored by The University of Texas Health Science Center, Houston. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by The University of Texas Health Science Center, Houston · Not applicable, Interventional, and Supportive care

Updated Oct 23, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess changes in the outcome of exercise behavior between the SPIN exercise-training condition and the WEllness for Longevity Living (WELL) attention/contact wellness control condition and to examine differences in exercise behavior, functioning, disability, and health between the SPIN and WELL conditions

02

Conditions studied

  • Multiple Sclerosis

Keywords

  • exercise
03

In context

Multiple Sclerosis

3,524 studies on the registry are indexed under Multiple Sclerosis; 668 are open to participants now.

This study's planned enrollment of 100 is above the median of 50 across 2,386 interventional studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

The University of Texas Health Science Center, Houston is the lead sponsor of 897 studies on the registry; 214 are open to participants now.

Of its 173 completed or terminated interventional studies of FDA-regulated products, 142 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of multiple sclerosis (MS).
  • Self-reported use of a wheelchair (manual wheelchair, power wheelchair, or scooter) ≥50% of the time.
  • Relapse-free for the past 30 days.
  • Godin Leisure Time Exercise Questionnaire Health Contribution Score \<14 units (i.e., not meeting current physical activity guidelines).

Exclusion criteria

Exclusion Criteria:

  • An MS relapse within the past 30 days
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    SPIN exercise-training condition

    Behavioral: SPIN exercise-training

  • Active comparator
    WELL attention/contact wellness control condition

    Behavioral: Control Condition (WELL)

Interventions

  • BehavioralSPIN exercise-training

    Participants complete three days of both modalities each week, with at least one day of rest between resistance sessions. For the first two weeks, all participants begin at 10-minute aerobic sessions and 1 set of 10 repetitions of five resistance exercises. The aerobic goal is to progress to 30-minute sessions (90 minutes/week) using a cycle (arm) ergometer; the resistance goal is 2 sets of 15 repetitions of 10 exercises (\~60 minutes/week). After two weeks, participants select one of three progression tracks (white, blue, or orange) with their coach. The final overall goal is 30 minutes of aerobic exercise plus 10 resistance exercises for two sets of 15 repetitions, three days per week (\~150 minutes/week of MVPA).The total time is 16 weeks.

  • BehavioralControl Condition (WELL)

    The WELL attention/contact control mirrors SPIN in coaching schedule and materials but focuses on health behaviors other than physical activity (diet, emotions, stress, sleep, fatigue, and falls). It is based on Social Cognitive Theory (SCT) principles and integrates National Multiple Sclerosis Society (NMSS) wellness resources. WELL includes 12 newsletters (Diet, Sleep, Stress, Balance, Cognition, and Fatigue).

06

What researchers measure

Primary outcomes

  1. Change in self reported total minutes per week of moderate-to-vigorous physical activity (MVPA)

    Time frame: Baseline , 16 weeks.

  2. Change in strength training, assessed by the Leisure Time Physical Activity Questionnaire for People with Disabilities (LTPAQ-D)

    Participants report the number of days and average minutes per day spent in mild-, moderate-, and vigorous-intensity aerobic activities during the previous 7 days. Weekly minutes are calculated separately for each intensity and summed to obtain total aerobic physical activity, expressed in minutes per week. Higher values indicate greater participation in leisure-time aerobic physical activity

    Time frame: Baseline , 16 weeks

Secondary outcomes

  1. Change in device-measured exercise behavior

    Physical activity is measured using an ActiGraph GT3X+ triaxial accelerometer worn on the non-dominant wrist for 7 consecutive days. Acceleration data from the three axes are combined to derive vector magnitude activity counts. Total vector magnitude activity counts are calculated using the study-specified accelerometer data processing and aggregation methods.

    Time frame: Baseline , 16 weeks

  2. Change in Upper-limb function as assessed by the Nine-Hole Peg Test

    Upper-limb dexterity is assessed using the Nine-Hole Peg Test (NHPT). Participants are instructed to place nine pegs into a pegboard and remove them as quickly as possible. Performance is measured by the time required to complete the task, recorded in seconds. A decrease in completion time indicates improved manual dexterity.

    Time frame: Baseline , 16 weeks

  3. Change in Upper-limb function as assessed by the Grip strength using the hand dynamometer

    Grip strength is assessed using a hand dynamometer. Participants squeeze the dynamometer according to the study protocol, and grip strength is recorded in kilograms s. An increase in grip strength indicates improved grip force.

    Time frame: Baseline , 16 weeks

  4. Change in Disability / Activities of Daily Living ( ADL) as assessed by the Barthel Index score

    The Barthel Index will be used to assess changes in participants' independence in activities of daily living (ADLs), including feeding, bathing, grooming, dressing, bowel and bladder control, toilet use, transfers, mobility, and stair climbing. Total scores range from 0 to 100 with higher scores indicating greater independence and lower scores indicating greater dependence.

    Time frame: Baseline , 16 weeks

  5. Change in Health-Related Quality of Life as assessed by the Multiple Sclerosis Impact Scale-29 (MSIS-29)

    The Multiple Sclerosis Impact Scale-29 (MSIS-29) is a 29-item, patient-reported outcome measure that assesses the physical and psychological impact of multiple sclerosis on health-related quality of life. The scale includes 20 physical-impact items and 9 psychological-impact items. Scores are transformed to a 0-100 scale, with higher scores indicating greater impact of multiple sclerosis and worse health-related quality of life.

    Time frame: Baseline , 16 weeks

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2029, 23 months later.

Of 868 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 23 months is close to that.

Counting every sponsor, half of 889 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2026
First posted
Oct 23, 2026
StartEst.
Jan 4, 2027
Primary completionEst.
Jan 2, 2029
CompletionEst.
Feb 5, 2029
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07891520
Collaborators
National Multiple Sclerosis Society
Responsible party
Stephanie Lee Silveira (Assistant Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Oct 23, 2026
Start date
Jan 4, 2027 (estimated)
Primary completion
Jan 2, 2029 (estimated)
Completion
Feb 5, 2029 (estimated)
Last update
Oct 23, 2026

Study contacts

Stephanie L Silveira, PhD
Contact
Stephanie.L.Silveira@uth.tmc.edu
(713) 500-9484
Rachel Barnes
Contact
Rachel.Barnes.1@uth.tmc.edu
(713) 500 9464
Stephanie L Silveira, PhD
principal investigator · The University of Texas Health Science Center, Houston

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion